DOCSLIB.ORG

The Glycemic Control Implementation Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Glycemic Control Implementation Guide Second Edition THE GLYCEMIC CONTROL IMPROVING GLYCEMIC CONTROL, PREVENTING IMPLEMENTATION GUIDE: HYPOGLYCEMIA AND Editors: OPTIMIZING CARE OF Greg Maynard, MD, MSc, SFHM (Lead Editor) THE INPATIENT WITH Karrie Berg, DO, MA Kristen Kulasa, MD HYPERGLYCEMIA Cheryl O’Malley, MD, FACP, FHM Kendall M. Rogers, MD, CPE, FACP, SFHM AND DIABETES 1 Improving Acute Coronary Syndrome Care for Hospitalized Patients Section 1: Essential First Steps Copyright ©2015 by Society of Hospital Medicine. All rights reserved. No part of this publication may be reproduced, stored in retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written consent. For more information or to obtain additional copies contact SHM at: Phone: 800-843-3360 Website: www.hospitalmedicine.org/gc 2 Improving Acute Coronary Syndrome Care for Hospitalized Patients Table of Contents Executive Summary ......................................................................................................................9 How to Use This Guide ................................................................................................................11 Section I: Take First Steps ..........................................................................................................12 A. Assess the Current State of Glycemic Management at a High Level ..................................... 14 B. Obtain Institutional Support ..................................................................................... 18 C. Form an Interdisciplinary Team ................................................................................ 19 D. Establish Team Rules ............................................................................................ 21 E. Define Scope, Priorities and General Goals of ourY Efforts ................................................ 22 F. Review the Framework for QI and QI Tools ................................................................... 23 G. Conclusion ......................................................................................................... 23 Section II: Identify Best Practices for Management of the Hospitalized Patient .....................24 with Diabetes/Hyperglycemia A. Background ........................................................................................................ 25 B. Monitoring Glucose Levels and HbA1c ........................................................................ 25 C. Glycemic Targets ................................................................................................. 26 D. Methods To Achieve Control .................................................................................... 27 1. Subcutaneous Insulin ............................................................................................................................. 27 2. Insulin Infusion and transition to Subcutaneous .................................................................................... 28 E. Transition to the Outpatient Setting ............................................................................ 28 F. Conclusion ......................................................................................................... 28 Section III: Assess Current State of Glycemic Management ....................................................30 A. Performing a Comprehensive Local Assessment of Current Care Processes ........................... 31 B. Current Glycemic Performance ................................................................................. 31 C. Electronic Medical Record (EMR) Review .................................................................... 33 D. Process Flow Mapping: A Critical QI Tool ..................................................................... 33 E. Individual Glycemic Control Process Assessment Items ................................................... 36 F. External Assessment Tools ...................................................................................... 42 3 Table of Contents (continued) Section IV: Choose Metrics and Develop a Data Collection Plan for Your ...............................43 Glycemic Control Program A. Introduction ........................................................................................................ 44 B. Process Measures ................................................................................................ 44 C. Other Measures ................................................................................................... 45 D. Outcome Measures and Glucometrics Introduction ......................................................... 45 E. Measuring Glycemic Control: Glucometrics .................................................................. 46 1. Defining the Target Patient Population ................................................................................................... 46 2. Which Glucose Values to Include and Exclude ....................................................................................... 47 3. Units of Analysis .................................................................................................................................... 48 4. Glucometric Measures ........................................................................................................................... 50 5. Regulatory Measures ............................................................................................................................. 52 F. External Sources to Obtain Glucometrics and Benchmarking .............................................. 53 G. Effective Presentation of Data .................................................................................. 57 H. Conclusion ......................................................................................................... 59 Section V.1: Overview - Designing and Implementing Protocols for ........................................62 Optimal Inpatient Glycemic Control A. Five Key Principles for Effective Implementation and Clinical Decision Support ...................... 63 B. Layering Interventions to Reinforce the Protocol and the Hierarchy of Reliability ..................... 66 C. Action-Oriented Learning: Plan–Do–Study–Act .............................................................. 69 Section V.2: Inpatient Glycemic Management Teams — Traits of High-Performing Teams ....72 A. Team Design (Make-up) ......................................................................................... 73 B. Five Important Characteristics for an Effective Inpatient Management Team ........................... 73 C. Team Extenders ................................................................................................... 75 D. Day-to-Day Management ........................................................................................ 76 Section V.3: Subcutaneous Insulin Order Sets and Protocols: ..................................................78 Effective Design and Implementation Strategies A. Identifying and Incorporating Key Concepts and Best Practices ........................................... 79 B. Standardize the Monitoring of Blood Glucose Values and Glycosylated Hemoglobin .................. 80 C. Establish a Target Range for Blood Glucose in Non-Critical Care Areas ................................. 80 D. Prompt Clinicians to Consider Discontinuing Oral Agents ................................................. 81 E. Incorporate Nutritional Management .......................................................................... 81 F. Access Diabetes Education and Appropriate Consultation ................................................. 81 G. Prescribe Physiologic (‘‘Basal-Nutritional-Correction Dose’’) Insulin Regimens ...................... 81 H. Special Situations ................................................................................................ 86 I. Plan for Discharge and Provide Guidance for the Transition ............................................... 87 J. Pulling It All Together: Make Sure Your Protocol/Order Set Is Easy to Use and Widely Utilized ..... 87 K. Monitor the Use and Effectiveness of Your Protocols and Order Sets .................................... 91 L. Conclusion ......................................................................................................... 91 4 Improving Glycemic Control Table of Contents (continued) Section V.4: Designing and Implementing Insulin Infusion Protocols and Order Sets ............93 A. Preparing to Implement an IIP .................................................................................. 93 B. Elements of an Optimal Insulin Infusion Protocol ........................................................... 96 C. Implementation: Addressing Safety Issues ................................................................... 99 D. Implementation: Educating And Engaging Nursing and Physician Staff.................................101 E. Implementation: Addressing Common Clinical Situations ................................................102 F. Assessing the Impact of Your Efforts: Follow-Up and Follow-Through ..................................103 G. Conclusion ........................................................................................................104 Section V.5: Design and Implement a DKA Protocol and Order Set ........................................106 A. Diagnosis 106 B. Monitoring ........................................................................................................106
Load more

Recommended publications
  • Therapeutic Medications Against Diabetes: What We Have and What We Expect
    Advanced Drug Delivery Reviews 139 (2019) 3–15 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Therapeutic medications against diabetes: What we have and what we expect Cheng Hu a,b, Weiping Jia a,⁎ a Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, People's Republic of China b Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, 6600 Nanfeng Road, Shanghai 200433, People's Republic of China article info abstract Article history: Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and Received 28 June 2018 high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related compli- Received in revised form 1 September 2018 cations. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Accepted 27 November 2018 Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of Available online 5 December 2018 these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidia- betic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes Keywords: fi Diabetes control, with its greater ef ciency, increased bioavailability, decreased toxicity and reduced dosing frequency. Treatment Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great poten- Drug delivery tial in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment.
    [Show full text]
  • Higher Mortality Rate in Moderate-To-Severe Thoracoabdominal Injury Patients with Admission Hyperglycemia Than Nondiabetic Normoglycemic Patients
    International Journal of Environmental Research and Public Health Article Higher Mortality Rate in Moderate-to-Severe Thoracoabdominal Injury Patients with Admission Hyperglycemia Than Nondiabetic Normoglycemic Patients 1, 2, 1 1 1 Wei-Ti Su y, Shao-Chun Wu y , Sheng-En Chou , Chun-Ying Huang , Shiun-Yuan Hsu , 1, , 3, , Hang-Tsung Liu z * and Ching-Hua Hsieh z * 1 Department of Trauma Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University and College of Medicine, Kaohsiung 83301, Taiwan; [email protected] (W.-T.S.); [email protected] (S.-E.C.); [email protected] (C.-Y.H.); [email protected] (S.-Y.H.) 2 Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University and College of Medicine, Kaohsiung 83301, Taiwan; [email protected] 3 Department of Plastic Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University and College of Medicine, Kaohsiung 83301, Taiwan * Correspondence: [email protected] (H.-T.L.); [email protected] (C.-H.H.) These authors contribute equally to this paper as the first author. y These authors contribute equally to this paper as the corresponding author. z Received: 21 August 2019; Accepted: 23 September 2019; Published: 25 September 2019 Abstract: Background: Hyperglycemia at admission is associated with an increase in worse outcomes in trauma patients. However, admission hyperglycemia is not only due to diabetic hyperglycemia (DH), but also stress-induced hyperglycemia (SIH). This study was designed to evaluate the mortality rates between adult moderate-to-severe thoracoabdominal injury patients with admission hyperglycemia as DH or SIH and in patients with nondiabetic normoglycemia (NDN) at a level 1 trauma center.
    [Show full text]
  • Postoperative Tight Glycemic Control
    Wang et al. BMC Endocrine Disorders (2018) 18:42 https://doi.org/10.1186/s12902-018-0268-9 RESEARCHARTICLE Open Access Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis Yuan-yuan Wang1, Shuang-fei Hu2, Hui-min Ying1, Long Chen2, Hui-li Li1, Fang Tian1 and Zhen-feng Zhou2* Abstract Background: The benefit results of postoperative tight glycemic control (TGC) were controversial and there was a lack of well-powered studies that support current guideline recommendations. Methods: The EMBASE, MEDLINE, and the Cochrane Library databases were searched utilizing the key words “Blood Glucose”, “insulin” and “Postoperative Period” to retrieve all randomized controlled trials evaluating the benefits of postoperative TGC as compared to conventional glycemic control (CGC) in patients undergoing surgery. Results: Fifteen studies involving 5053 patients were identified. As compared to CGC group, there were lower risks of total postoperative infection (9.4% vs. 15.8%; RR 0.586, 95% CI 0.504 to 0.680, p < 0.001) and wound infection (4. 6% vs. 7.2%; RR 0.620, 95% CI 0.422 to 0.910, p = 0.015) in TGC group. TGC also showed a lower risk of postoperative short-term mortality (3.8% vs. 5.4%; RR 0.692, 95% CI 0.527 to 0.909, p = 0.008), but sensitivity analyses showed that the result was mainly influenced by one study. The patients in the TGC group experienced a significant higher rate of postoperative hypoglycemia (22.3% vs. 11.0%; RR 3.145, 95% CI 1.928 to 5.131, p < 0.001) and severe hypoglycemia (2.8% vs.
    [Show full text]
  • Prevention of Stress Hyperglycemia with the Use of DPP-4 Inhibitors in Non-Diabetic Patients Undergoing Non-Cardiac Surgery, a Pilot Study (SITA-SURGERY PILOT TRIAL)
    Title: Prevention of stress hyperglycemia with the use of DPP-4 inhibitors in non-diabetic patients undergoing non-cardiac surgery, a Pilot Study (SITA-SURGERY PILOT TRIAL). Principal Investigator: Maya Fayfman, M.D. Instructor of Medicine Department of Medicine/Endocrinology Emory University School of Medicine Co-Investigators: Department of Medicine: Guillermo Umpierrez, MD, Priyathama Vellanki, MD, David Reyes, MD, Georgia Davis, MD, Saumeth Cardona, David Chachkhiani, Clementina Ramos Garrido, David Alfa, and Maria Urrutia Department of Surgery: Sheryl Gabram-Mendola and MD, Mara Schenker, MD Department of Anesthesiology Elizabeth Duggan, MD, Jay Sanford MD and Joanna Schindler MD School of Public Health Limin Peng, PhD Investigator-Sponsor: Guillermo Umpierrez, MD. Division of Endocrinology, Department of Medicine ABSTRACT Approximately 51.4 million surgical procedures are performed in the United States each year.1 Over 40% of patients both with and without diabetes (DM) develop stress hyperglycemia (defined as a BG >140 mg/dl) after general surgery.2,3 Compared to patients without DM, those with DM have higher rates of complications that include wound infections,4,5 acute renal failure,6 longer hospital stay,7,8 and perioperative mortality.8,9 However, non-DM patients with stress hyperglycemia have poor surgical outcome after cardiac surgery with even higher rates of complications and mortality compared to those with DM.10,11 Few observational studies looking at non- cardiac patients have found that stress hyperglycemia is associated
    [Show full text]
  • Intensive Insulin Therapy for Tight Glycemic Control Research Therapy Monitoring Nursing
    Proceedings from The Seventh Conference The CareFusion Center for Safety and Clinical Excellence June 7-8, 2007, San Diego, CA Philip J. Schneider, MS, FASHP, Editor Intensive Insulin Therapy for Tight Glycemic Control Research Therapy Monitoring Nursing Conference Report Published by The CareFusion Center for Safety and Clinical Excellence www.cardinalhealth.com/clinicalcenter International Conference on Intensive Insulin Therapy for Tight Glycemic Control The seventh invitational conference at the CareFusion Center for Safety and Clinical Excellence in San Diego, held June 7-8, 2007, brought together a distinguished faculty from clinical practice, academia, and organizations. Judith Jacobi, PharmD, FCCM, FCCP, BCPS, Critical Care Pharmacist, Methodist Hospital/Clarian Health, Indianapolis, IN and Timothy S. Bailey, MD, FACE, CPI, Advanced Metabolic Care and Research, Escondido, CA chaired the conference. Internationally recognized experts on research, current issues and opportunities in the use of intensive insulin therapy for tight glycemic control (TGC IIT) presented. This conference report summarizes the information presented on TGC IIT with regard to research findings, safety concerns, emerging practices, monitoring, and nursing issues as researchers and clinicians seek to optimize insulin therapy to help maintain normoglycemia in critically ill patients. The proceedings were edited by Philip J. Schneider, MS, FASHP, Clinical Professor and Director, Latiolais Leadership Program, College of Pharmacy, The Ohio State University, Columbus,
    [Show full text]
  • Pharmacist Glycemic Control Team Associated with Improved
    At a Glance Original Research Practical Implications p e128 Author Information p e134 Full text and PDF www.ajmc.com Web exclusive Pharmacist Glycemic Control Team Associated With Improved Perioperative Glycemic and Utilization Outcomes David M. Mosen, PhD, MPH; Karen S. Mularski, MD; Richard A. Mularski, MD, MSHS, MCR; Ariel K. Hill, AB; and Elizabeth Shuster, MS atients with diabetes and stress hyperglycemia are frequently hospitalized for surgical procedures,1 and ABSTRACT recent estimates indicate that 30% to 50% of US inpa- Objectives: Perioperative hyperglycemia is a risk factor for P 1,2 tients have diabetes and/or hyperglycemia. Multiple studies increased surgical morbidity and mortality. Pharmacy-led manage- have documented the risks of perioperative hyperglycemia, ment teams may improve glycemic control and postoperative out- including poor surgical outcomes and higher readmission comes. We sought to determine whether a pharmacist-led glycemic control team is associated with improved glycemic control and rates.1-4 However, improved glycemic control leads to reduc- reduced postdischarge utilization and medical costs. tions in hospital complications, length of stay, and mortality.1,5-7 Study Design: Retrospective, observational study. Multiple professional societies, agencies, and task forces have issued guidelines recommending methods to achieve Methods: We assessed patient-level outcomes during a 12-month pre-intervention period and compared them at years 1 and 2 post safe and effective glycemic control in hospitalized patients.8-12 implementation at a tertiary care multi-specialty medical center. Although the optimal target glucose range for hospitalized The patients were noncritically ill postoperative surgical patients patients continues to evolve based on results of recent clini- followed 72 hours post surgery (days 1-3).
    [Show full text]
  • 2016 Standards of Medical Care in Diabetes
    THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION VOLUME 39 | SUPPLEMENT 1 WWW.DIABETES.ORG/DIABETESCARE JANUARY 2016 PLE M E P N U T S 1 AMERICAN DIABETES ASSOCIATION STANDARDS OF MEDICAL CARE IN DIABETES—2016 ISSN 0149-5992 American Diabetes Association Standards of Medical Care in Diabetesd2016 January 2016 Volume 39, Supplement 1 [T]he simple word Care may suffice to express [the journal’s] philosophical mission. The new journal is designed to promote better patient care by serving the expanded needs of all health professionals committed to the care of patients with diabetes. As such, the American Diabetes Association views Diabetes Care as a reaffirmation of Francis Weld Peabody’s contention that “the secret of the care of the patient is in caring for the patient.” —Norbert Freinkel, Diabetes Care, January-February 1978 EDITOR IN CHIEF William T. Cefalu, MD ASSOCIATE EDITORS EDITORIAL BOARD George Bakris, MD Nicola Abate, MD Rita Rastogi Kalyani, MD, MHS, FACP Lawrence Blonde, MD, FACP Silva Arslanian, MD Rory J. McCrimmon, MBChB, MD, FRCP Andrew J.M. Boulton, MD Angelo Avogaro, MD, PhD Harold David McIntyre, MD, FRACP David D’Alessio, MD Ananda Basu, MD, FRCP Gianluca Perseghin, MD Sherita Hill Golden, MD, MHS, FAHA John B. Buse, MD, PhD Anne L. Peters, MD Mary de Groot, PhD Sonia Caprio, MD Jonathan Q. Purnell, MD Eddie L. Greene, MD Robert Chilton, DO Peter Reaven, MD Frank B. Hu, MD, MPH, PhD Kenneth Cusi, MD, FACP, FACE Helena Wachslicht Rodbard, MD Derek LeRoith, MD, PhD Paresh Dandona, MD, PhD David J. Schneider, MD Robert G.
    [Show full text]
  • The Main Events in the History of Diabetes Mellitus
    Chapter 1 The Main Events in the History of Diabetes Mellitus Jacek Zajac, Anil Shrestha, Parini Patel, and Leonid Poretsky In Antiquity A medical condition producing excessive thirst, continuous urination, and severe weight loss has interested medical authors for over three millennia. Unfortunately, until the early part of twentieth century the prognosis for a patient with this condition was no better than it was over 3000 years ago. Since the ancient physicians described almost exclusively cases of what is today known as type 1 diabetes mellitus, the outcome was invariably fatal. Ebers Papyrus, which was written around 1500 BC, excavated in 1862 AD from an ancient grave in Thebes, Egypt, and published by Egyptologist Georg Ebers in 1874, describes, among various other ailments and their remedies, a condition of “too great emptying of the urine” – perhaps, the reference to diabetes mellitus. For the treatment of this condition, ancient Egyptian physicians were advocating the use of wheat grains, fruit, and sweet beer.1,2 Physicians in India at around the same time developed what can be described as the first clinical test for dia- betes. They observed that the urine from people with diabetes attracted ants and flies. They named the condition “madhumeha” or “honey urine.” Indian physicians also noted that patients with “madhumeha” suffered from extreme thirst and foul breath (probably, because of ketosis). Although the polyuria associated with diabetes was well recognized, ancient clinicians could not distinguish between the polyuria due to what we now call diabetes mellitus from the polyuria due to other conditions.3 Around 230 BC, Apollonius of Memphis for the first time used the term “diabetes,” which in Greek means “to pass through” (dia – through, betes – to go).
    [Show full text]
  • The Association of Admission Blood Glucose Level with the Clinical Picture and Prognosis in Cardiogenic Shock – Results from the Cardshock Study☆
    International Journal of Cardiology 226 (2017) 48–52 Contents lists available at ScienceDirect International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock – Results from the CardShock Study☆ Anu Kataja a,⁎,1, Tuukka Tarvasmäki a,1,JohanLassusb,1, Jose Cardoso c,1, Alexandre Mebazaa d,1,LarsKøbere,1, Alessandro Sionis f,1, Jindrich Spinar g,1, Valentina Carubelli h,1, Marek Banaszewski i,1, Rossella Marino j,1, John Parissis k,1, Markku S. Nieminen b,1, Veli-Pekka Harjola a,1 a Emergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland b Cardiology, University of Helsinki, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland c CINTESIS - Center for Health Technology and Services Research, Department of Cardiology, Faculty of Medicine, University of Porto, São João Medical Center, Porto, Portugal d INSERM U942, Hopital Lariboisiere, APHP and University Paris Diderot, Paris, France e Rigshospitalet, Copenhagen University Hospital, Division of Heart Failure, Pulmonary Hypertension and Heart Transplantation, Copenhagen, Denmark f Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Universitat de Barcelona, Barcelona, Spain g Internal Cardiology Department, University Hospital Brno and Masaryk University, Brno, Czech republic h Division
    [Show full text]
  • Post-Operative Stress Hyperglycemia Is a Predictor of Mortality in Liver
    Giráldez et al. Diabetol Metab Syndr (2018) 10:35 https://doi.org/10.1186/s13098-018-0334-5 Diabetology & Metabolic Syndrome RESEARCH Open Access Post‑operative stress hyperglycemia is a predictor of mortality in liver transplantation Elena Giráldez1* , Evaristo Varo2, Ipek Guler3, Carmen Cadarso‑Suarez3, Santiago Tomé2, Patricia Barral1, Antonio Garrote1 and Francisco Gude4 Abstract Background: A signifcant association is known between increased glycaemic variability and mortality in critical patients. To ascertain whether glycaemic profles during the frst week after liver transplantation might be associated with long-term mortality in these patients, by analysing whether diabetic status modifed this relationship. Method: Observational long-term survival study includes 642 subjects undergoing liver transplantation from July 1994 to July 2011. Glucose profles, units of insulin and all variables with infuence on mortality are analysed using joint modelling techniques. Results: Patients registered a survival rate of 85% at 1 year and 65% at 10 years, without diferences in mortal‑ ity between patients with and without diabetes. In glucose profles, however, diferences were observed between patients with and without diabetes: patients with diabetes registered lower baseline glucose values, which gradually rose until reaching a peak on days 2–3 and then subsequently declined, diabetic subjects started from higher values which gradually decreased across the frst week. Patients with diabetes showed an association between mortality and age, Model for End-Stage Liver Disease score (MELD) score and hepatitis C virus; among non-diabetic patients, mortal‑ ity was associated with age, body mass index, malignant aetiology, red blood cell requirements and parenteral nutri‑ tion. Glucose profles were observed to be statistically associated with mortality among patients without diabetes (P 0.022) but not among patients who presented with diabetes prior to transplantation (P 0.689).
    [Show full text]
  • Tight Glycemic Control and Use of Hypoglycemic Medications in Older
    588 Diabetes Care Volume 38, April 2015 Carolyn T. Thorpe,1,2 Walid F. Gellad,1,3 Tight Glycemic Control and Use of Chester B. Good,1,2,3,4 Sijian Zhang,1 Xinhua Zhao,1,4 Maria Mor,1,5 and Hypoglycemic Medications in Michael J. Fine1,3 Older Veterans With Type 2 Diabetes and Comorbid Dementia Diabetes Care 2015;38:588–595 | DOI: 10.2337/dc14-0599 OBJECTIVE Older adults with diabetes and dementia are at increased risk for hypoglycemia and other adverse events associated with tight glycemic control and are unlikely to experience long-term benefits. We examined risk factors for tight glycemic control in this population and use of medications associated with a high risk of hypoglycemia in the subset with tight control. EPIDEMIOLOGY/HEALTH SERVICES RESEARCH RESEARCH DESIGN AND METHODS This retrospective cohort study of national Veterans Affairs (VA) administrative/ clinical data and Medicare claims for fiscal years (FYs) 2008–2009 included 15,880 veterans aged ‡65 years with type 2 diabetes and dementia and prescribed antidi- abetic medication. Multivariable regression analyses were used to identify socio- demographic and clinical predictors of hemoglobin A1c (HbA1c) control (tight, moderate, poor, or not monitored) and, in patients with tight control, subsequent use of medication associated with a high risk of hypoglycemia (sulfonylureas, insulin). RESULTS 1Center for Health Equity Research and Promo- Fifty-two percent of patients had tight glycemic control (HbA1c <7% [53 mmol/mol]). fi tion, Veterans Affairs Pittsburgh Healthcare Sys- Speci c comorbidities, older age, and recent weight loss were associated with tem, Pittsburgh, PA greater odds of tight versus moderate control, whereas Hispanic ethnicity and obe- 2Department of Pharmacy and Therapeutics, sity were associated with lower odds of tight control.
    [Show full text]
  • Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life
    pharmacy Article Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life Anne-Sophie Mangé 1, Arnaud Pagès 1,2,3,* , Sandrine Sourdet 4, Philippe Cestac 1,2 and Cécile McCambridge 1 1 Department of Pharmacy, Toulouse University Hospital, UPS Toulouse III Paul Sabatier University, 31000 Toulouse, France; [email protected] (A.-S.M.); [email protected] (P.C.); [email protected] (C.M.) 2 UMR 1027, Inserm, UPS Toulouse III Paul Sabatier University, 31000 Toulouse, France 3 INSPIRE Project, Institute of Aging, Gérontopôle, Toulouse University Hospital, UPS Toulouse III Paul Sabatier University, 31000 Toulouse, France 4 Geriatric Department, Toulouse University Hospital, UPS Toulouse III Paul Sabatier University, 31000 Toulouse, France; [email protected] * Correspondence: [email protected]; Tel.: +33-567-776-418 Abstract: (1) Background: The latest recommendations for diabetes management adapt the objectives of glycemic control to the frailty profile in older patients. The purpose of this study was to evaluate the proportion of older patients with diabetes whose treatment deviates from the recommendations. (2) Methods: This cross-sectional observational study was conducted in older adults with known diabetes who underwent an outpatient frailty assessment in 2016. Glycated hemoglobin (HbA1c) target is between 6% and 7% for nonfrail patients and between 7% and 8% for frail patients. Frailty was evaluated using the Fried criteria. Prescriptions of glucose-lowering drugs were analyzed based on explicit and implicit criteria. (3) Results: Of 110 people with diabetes with an average age of Citation: Mangé, A.-S.; Pagès, A.; 81.7 years, 67.3% were frail.
    [Show full text]